Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

Table 3 Comparison within the tenofovir disoproxil fumarate group after treatment, mean ± SE

TDF	0 week	96 weeks	(0 week vs 96 weeks)
WBC	6.27 ± 0.45	6.87 ± 0.63	0.443861557
Hb	147.79 ± 3.88	147.50 ± 5.80	0.967641272
PLT	234.00 ± 15.58	239.14 ± 11.38	0.791953625
ALT	176.42 ± 53.02	20.62 ± 3.63	0.00922277
AST	99.85 ± 28.31	22.75 ± 1.15	0.011908537
Cr	67.25 ± 5.17	77.49 ± 5.63	0.192832703
CLCR	112.04 ± 7.11	90.04 ± 6.85	0.036435267
PHOS	1.09 ± 0.07	1.23 ± 0.27	0.611661657
GLU	4.73 ± 0.11	4.77 ± 0.14	0.80941735
TG	1.15 ± 0.20	2.42 ± 1.32	0.332101848
CHOL	4.77 ± 0.20	3.97 ± 0.19	0.008550427
HDL	1.45 ± 0.10	1.14 ± 0.10	0.033296713
LDL	2.74 ± 0.17	2.23 ± 0.17	0.046729094
FIB-4	1.28 ± 0.29	1.12 ± 0.39	0.742777384
CAP	212.07 ± 13.44	185.17 ± 6.02	0.09703147
miR3	5.33 ± 0.60	2.35 ± 0.69	0.003107141
RNA	3.99 ± 0.86	1.29 ± 0.68	0.024764947
DNA	7.20 ± 0.28	0.29 ± 0.29	4.24 × 10-12
HBsAg	3.12 ± 0.25	2.92 ± 0.13	0.473322675
HBeAg	1.33 ± 0.54	-0.03 ± 0.32	0.040841537

TDF: Tenofovir disoproxil fumarate; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.